IRANIAN PROPOLIS SUPPLEMENT DECREASES THE INFLAMMATORY INTERLEUKINS IN PATIENTS WITH TYPE 2 DIABETES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL

Background and Aim: Propolis, an important honeybee product, have ethno pharmacological nutrients since ancient times. It has a wide range of alleged applications including potential anti-inflammatory and antioxidant effects. The aim of this study was the investigation of the anti-inflammatory activity of Iranian propolis in type 2 diabetes mellitus (T2DM).Methods: In the 8-week randomized double-blind controlled study, enrolled 60 patients with T2DM were randomly assigned to propolis group (n = 30) and control group (n =30). Propolis group received 500 mg three times a day for a total of 1500 mg/d of propolis pills, while the control group received similar pills, lacking propolis. Interleukin 6 and Interleukin 17 were measured at the baseline and at the end of the study. Statistical analysis was performed using SPSS software.Results: Eight weeks after drug administration, was a significant difference in mean IL-6 changes (p=0.017) between the two groups, and IL-17 in propolis treated group significantly decreased (p=0.02) in comparing with control group. Within groups analysis, the propolis group showed remarkable changes in IL-6 (P<0.031) and IL-17 (P<0.015). There was no significant reduction in IL-6 and IL-17 in the placebo group. The difference in the two groups was significant.Conclusion: Based on this study, the daily intake of 1500 mg of Iranian propolis supplement for 8 weeks led to decrease inflammatory factors IL-6 and IL-17 in patients with T2D.

Keywords:

Propolis , Inflammatory Factors , Diabetes Mellitus , interleukin 6 , interleukin 17